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Purpose: Ketorolac 0.45% is a new formulation of topical ketorolac in which preservative 
(benzalkonium chloride, BAK) was removed and carboxymethylcellulose (CMC) was added to 
improve tolerability and reduce dosing frequency. This study compared the effects of ketorolac 
0.45% on corneal wound healing to prior ketorolac formulations (0.4% and 0.5%), bromfenac 
0.09%, and nepafenac 0.1%.
Methods: Two parallel-group comparisons were performed in series. A 5-mm central epithelial 
wound was made in fresh porcine corneas. After 24 hours in minimum essential medium 
(MEM), corneas were incubated for 10 minutes with study drugs, Triton X-100 1% (positive 
control), or MEM (negative control), followed by 24 hours in MEM. The remaining wound 
area was stained, photographed, and quantified (pixels). Study 1 compared ketorolac 0.45% to 
ketorolac 0.4% and ketorolac 0.5%. Study 2 compared ketorolac 0.45% to bromfenac 0.09% 
and nepafenac 0.1%.
Results: The mean (±SD) original wound area was 200,506 ± 4,363 pixels, which was reduced 
to 59,509 ± 4850 at 48 hours after exposure to Triton X-100 1%. In study 1, the mean remain-
ing wound areas at 48 hours in pixels were 2969 ± 1633 with MEM, 586 ± 299 with ketorolac 
0.45% (significantly reduced, P , 0.05 vs all other treatments), 10,228 ± 7541 with ketorolac 
0.4%, and 50,674 ± 33,409 with ketorolac 0.5% (significantly enlarged, P , 0.05 vs MEM). 
In study 2, the mean remaining wound areas at 48 hours were 565 ± 1263 with MEM, 322 ± 229 
with ketorolac 0.45% (significantly reduced, P , 0.01 vs bromfenac 0.09% and nepafenac 
0.1%), 29,093 ± 14,295 with bromfenac 0.09% (significantly enlarged, P ,0.01 vs MEM) 
and 47,322 ± 13,736 with nepafenac 0.1% (significantly enlarged, P , 0.01 vs MEM and vs 
bromfenac 0.09%).
Conclusion: Corneas treated with ketorolac 0.45% healed as rapidly as those treated with MEM, 
likely secondary to addition of CMC and removal of BAK. In the ex vivo corneal organ culture 
model, ketorolac 0.45% had statistically less impact on corneal re-epithelialization than prior 
ketorolac formulations (0.4% and 0.5%), bromfenac 0.09%, and nepafenac 0.01%.
Keywords: bromfenac 0.09%, corneal epithelial wound healing, epithelial toxicity, ketorolac 
0.45%, nepafenac 0.1%, ocular surgery
Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDS) have anti-inflammatory, analgesic, 
and antipyretic properties.1 NSAIDS primarily act as cyclooxygenase inhibitors and 
limit the production of endogenous prostaglandins in the arachidonic acid cascade.2,3 
Topical NSAIDS are commonly used in ophthalmology to control postopera-
tive inflammation, reduce pain following refractive surgery, inhibit intraoperative 
  miosis, and treat allergic conjunctivitis.4,5 Commercially available topical NSAIDS Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
270
Xu et al
may differ in the type and concentration of the active 
agent,   concentration of preservative, pH, and/or additional 
surfactants.
Topical NSAIDS have been associated with corneal 
complications which include superficial punctate keratopa-
thy, subepithelial infiltrates, epithelial defects, delayed 
epithelial healing, corneal anesthesia, ulceration, and 
perforation.6–12 While corneal epithelial toxicity has been 
attributed to both the active agents and the preservatives 
within topical formulations as well as pre-existing systemic 
conditions, keratitis, corneal ulceration, and perforation 
have all been reported in patients using preservative-free 
formulations.8,13,14 Animal studies have suggested that 
the corneal toxicity of topical NSAIDS may result from 
an upregulation of matrix metalloproteinases (MMPs), 
endopeptidases involved in the remodeling of the corneal 
extracellular matrix.15
As topical NSAIDs are commonly used in the periopera-
tive setting, it is critical to develop formulations that do not 
inhibit epithelial healing. Topical ketorolac, first introduced 
in 1993, remains the most commonly used ophthalmic 
NSAID. Ophthalmic ketorolac 0.45% solution (Acuvail®, 
Allergan, Inc., Irvine, CA) was developed to maintain the 
efficacy of prior formulations of ketorolac while enhancing 
tolerability and reducing the dosing regimen. Changes in 
the new formulation, ketorolac 0.45%, include the removal 
of the preservative (BAK) and the surfactant (octoxynal 
40) and the addition of carboxymethylcellulose (CMC) 
(Table 1), which prolongs drug retention on the eye, pro-
tects the ocular surface, and may also promote corneal 
re-epithelialization.16,17
A porcine corneal model of wound healing was devel-
oped which has previously been used to assess the role of 
growth factors in corneal re-epithelialization.18,19 Given the 
changes in the formulation of ketorolac, the present study 
was designed to compare the impact on wound healing of 
the new formulation of ketorolac 0.45% to prior generations 
of ketorolac (0.4% and 0.5%) as well as to bromfenac 0.09% 
and nepafenac 0.1%.
Methods
Two parallel-group comparisons were performed in series 
to evaluate epithelial wound closure in an ex vivo porcine 
corneal organ culture model that has been previously 
described.18,19 In the first experiment, epithelial debrided 
porcine corneas were exposed to different formulations of 
the ketorolac molecule, namely ketorolac 0.45% (Acuvail®, 
Allergan, Inc.), ketorolac 0.4% (Acular LS®; Allergan, 
Inc.), and ketorolac 0.5% (Acular®, Allergan, Inc.). In the 
second experiment, ketorolac 0.45% was compared to 
bromfenac 0.09% (Xibrom®, Ista Pharmaceuticals, Irvine, 
CA) and nepafenac 0.1% (Nevanac®, Alcon Laboratories,   
Fort Worth, TX).
In brief, porcine eyes were obtained from a local abattoir, 
transported to the laboratory on ice in a moist chamber, 
and processed for corneal culture on the same day. An 
epithelial wound was made by demarcating an area on the 
central cornea with a 5-mm trephine and then removing the 
epithelium within the circle with a small scalpel, leaving 
an intact basement membrane. Corneal-scleral rims, with 
approximately 4 mm of the limbal conjunctiva present, were 
excised and rinsed in sterilized phosphate-buffered saline. 
The excised corneas were placed epithelial-side down into 
a sterile cup. The endothelial corneal concavity was then 
filled with minimum essential medium (MEM) containing 
1% agarose and 1 mg/mL rat tail tendon collagen maintained 
at 42°C. This mixture was allowed to gel. The cornea, along 
with its supporting gel, was inverted (endothelial side down) 
and then transferred to a 35-mm dish. The culture medium 
(∼2 mL) was added dropwise to the surface of central cornea 
until the limbal conjunctiva was covered, leaving the epithe-
lium exposed to the air. The corneas were then cultured in a 
humidified 5% CO2 incubator at 37°C in MEM for 24 hours 
to ensure initial wound recovery.
After 24 hours, a 50-µL volume of MEM, Triton X-100 
(1%; Dow Chemical Company, Midland, MI), or study drugs 
(ketorolac 0.45%, ketorolac 0.4%, ketorolac 0.5%, nepafenac 
0.01%, or bromfenac 0.09%) was applied to the epithelial 
wound surface for 10 minutes. MEM alone was used as a 
Table 1 Compositions of the study ophthalmic nsAiD solutions
Ketorolac 
0.45%
Ketorolac 
0.4%
Ketorolac 
0.5%
Bromfenac 
0.09%
Nepafenac 
0.1%
Preservative none 0.006% BAK 0.01% BAK 0.005% BAK 0.05% BAK
Other 
ingredients
CMC, na 
citrate
eDTA, 
octoxynol
eDTA, 
octoxynol
eDTA, na borate, 
Na sulfite, povidone, 
polysorbate 80
eDTA, mannitol, 
carbomer 947P, 
naCl, tyloxapol
ph 6.8 7.4 7.4 8.3 7.4
Abbreviations: BAK, benzalkonium chloride; CMC, carboxymethylcellulose; eDTA, ethylenediaminetetraacetic acid; na, sodium.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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negative control, and Triton X-100 was used as a positive 
control. Corneas were rinsed twice with 3 mL of phosphate-
buffered saline and incubated in 2 mL of fresh MEM for an 
additional 24 hours prior to staining. The remaining wound 
area was then stained with Richardson staining solution and 
photographed.20 The staining area was quantified (in pixels) 
using Adobe Photoshop® (Adobe Systems, Inc., San Jose, 
CA) as previously described. A total of five corneas was used 
in each treatment group.
Data were presented as the mean of remaining wound 
area ± standard deviation (SD). One way analysis of vari-
ance (ANOVA) with a Newman-Keuls posttest was used for 
statistical comparison among groups. A P-value of ,0.05 
was considered statistically significant.
Results
The mean (SD) original wound area induced by the 
5 mm   trephine was 200,506 ± 4363 pixels. At 48 hours, 
corneas treated with Triton X-100 1% had a mean (SD) 
remaining wound area of 59,509 ± 4850 pixels   (Figure 1). 
In study 1, the mean (SD) remaining wound areas at 
48 hours following treatment with MEM control, ketoro-
lac 0.45%, ketorolac 0.4%, and ketorolac 0.5% were 
2969 ± 1633 pixels, 586 ± 299 pixels, 10,228 ± 7541 pixels, 
and 50,674 ± 33,409 pixels, respectively (Figure 2). Corneas 
treated with ketorolac 0.45% had a significantly smaller mean 
remaining wound area than did corneas treated with MEM 
control, ketorolac 0.4%, and ketorolac 0.5% (P , 0.05). 
In contrast, the mean remaining wound area of corneas treated 
with ketorolac 0.5% was not statistically different than those 
treated with Triton X-100 1%.
In study 2, corneas treated with MEM control, ketorolac 
0.45%, bromfenac 0.09%, and nepafenac 0.1% had mean 
(SD) remaining wound areas at 48 hours of 565 ± 1263 
pixels, 322 ± 229 pixels, 29,093 ± 14,295 pixels, and 
47,322 ± 13,736 pixels, respectively (Figure 3). The remain-
ing wound areas were significantly smaller in corneas treated 
with ketorolac 0.45% as compared to those treated with 
  bromfenac 0.09% or nepafenac 0.1% (P , 0.01). Corneas 
treated with nepafenac 0.1% had a significantly larger mean 
remaining wound area than those treated with bromfenac 
0.09% (P , 0.01). The mean remaining wound area of cor-
neas treated with nepafenac 0.1% was not statistically differ-
ent from that of corneas treated with Triton X-100 1%.
Discussion
The use of topical NSAIDs for the treatment of postopera-
tive pain and inflammation has increased in recent years, and 
NSAIDs have now become an integral part of the periopera-
tive regimen.5 There remain, however, concerns about the 
impact of NSAIDs on corneal re-epithelialization following 
ocular surgery.14,21 Given the significance of reestablish-
ing a normal epithelial barrier, it is important to select a 
perioperative NSAID that does not interfere with epithelial 
wound healing.
In this ex vivo corneal organ culture model, the corneal 
epithelial wounds healed as rapidly with the ketorolac 0.45% 
formulation as with the MEM control. Significant differences 
in the rate of wound healing were found between both prior 
ketorolac formulations (ketorolac 0.5% and ketorolac 0.4%) 
and the new ketorolac 0.45% formulation, in which BAK 
was removed and CMC was added. In addition, significant 
differences in the rate of wound healing were observed when 
either bromfenac 0.09% or nepafenac 0.1% were compared 
to ketorolac 0.45%. Of note, the remaining wound areas 
at 48 hours following treatment with ketorolac 0.5% and 
nepafenac 0.1% were not statistically different from those 
after treatment with the positive control, Triton X-100 1%, 
a detergent known to jeopardize cell viability by disrupting 
cell membrane integrity.22
The mechanism by which ophthalmic NSAID solu-
tions delay wound healing is not precisely known. How-
ever, it has been shown in animal models that ophthalmic 
NSAID solutions may increase the expression of MMP-1 
(collagenase-1), MMP-2 (gelatinase A), and MMP-8 
(collagenase-2), which, in turn, may impair corneal wound 
healing by destroying newly deposited extracellular matrix, 
interrupting epithelial cell interaction, and disrupting 
epithelial basement membrane.15 The preservative BAK 
included in most ophthalmic NSAID solutions may also 
contribute to the delay in epithelial wound healing by induc-
ing inflammation, increasing transepithelial permeability, 
and decreasing epithelial vitality.23–25
Both the removal of the preservative as well as the addi-
tion of CMC in the ketorolac 0.45% formulation likely play 
Original wound Trition X-100
Figure 1 representative images of corneas with original wound and those following 
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a role in the similar impact on epithelial wound healing 
between ketorolac 0.45% and the MEM control. Despite 
a higher concentration of active agent relative to ketorolac 
0.4%, ketorolac 0.45% has significantly less effect on epi-
thelial wound healing. CMC has been shown to stimulate 
epithelial wound healing in animal models as well as in 
in vitro human corneal epithelial cells culture models.16,26 
Though the exact mechanism has yet to be determined, 
CMC has been shown to stimulate epithelial cell migration 
by binding to matrix proteins and facilitating epithelial cell 
attachments.16 The results of the current study also dem-
onstrate the role of the active ingredients in each topical 
NSAID, as significant differences were observed in the 
wound healing effect of bromfenac 0.09% and nepafenac 
0.1% despite equivalent concentrations of BAK.
There are a limited number of prospective clinical 
studies comparing the effects of topical NSAIDs on cor-
neal re-epithelialization, and most reports in the literature 
are based on retrospective case series. Durrie et al reported 
in a double-masked, randomized prospective study of 
eyes post-photorefractive keratectomy that ketorolac 
0.4% and nepafenac 0.1% treated eyes achieved complete 
  re-epithelialization significantly faster than bromfenac 
0.09% treated eyes, though these results may have been 
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Figure 2 remaining epithelial wound area in corneas treated with various ophthalmic solutions of ketorolac. representative images of corneas treated with ketorolac 0.5%, 
0.4%, and 0.45% A) and corresponding intensity of the wound area staining B) are shown.
Notes: aP , 0.05 compared to minimum essential medium (MeM) control; bP , 0.05 compared to ketorolac 0.45%; cP , 0.05 compared to all other treatments.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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affected by thrice daily treatment in each study arm and 
daily contact lens removal.6 A prospective, double-masked 
study in which one eye received ketorolac 0.4% and the 
fellow eye received nepafenac 0.1% following epi-laser 
in situ keratomileusis (LASIK) was halted after only 14 
eyes of 7 patients due to differences in wound healing 
(5.7 ± 1.1 days with ketorolac 0.4% vs 7.9 ± 2.1 days 
with nepafenac) and statistically significantly greater 
mean haze scores at week 2 and month 1 in eyes treated 
with nepafenac.12 In contrast, there was no difference in 
the rate of corneal epithelial wound healing between the 
eyes treated with nepafenac 0.1% and ketorolac 0.4% once 
the NSAIDs were instilled after placement of the bandage 
contact lens.27
The ex vivo model of corneal wound healing used in this 
study demonstrates that the addition of CMC and the removal 
of BAK in the new formulation of ketorolac 0.45% allows 
for more rapid corneal epithelial wound healing than prior 
ketorolac formulations, nepafenac 0.1%, and bromfenac 
0.09%. Limitations of the current study include the lack 
of treatment arms involving CMC or vehicle alone and the 
inability to fully assess the structural integrity of the healed 
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Figure 3 remaining epithelial wound area in corneas treated with nepafenac 0.1%, bromfenac 0.09%, and ketorolac 0.45%. representative images of corneas treated with 
nepafenac 0.1%, bromfenac 0.09%, and ketorolac 0.45% A) and corresponding intensity of the remaining wound area B) are shown.
Notes: aP , 0.001 compared to minimum essential medium (MeM) control; bP , 0.01 compared to ketorolac 0.45%; cP , 0.01 compared to bromfenac 0.09%.Clinical Ophthalmology
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corneal wounds. Ultimately, animal and in vitro models do 
not necessarily take into account differences in exposure 
times on the ocular surface or clinical dosing regimens. 
  Additional clinical studies directly comparing the effects of 
topical NSAIDs on wound healing are warranted to corrobo-
rate the results of the present study in porcine eyes.
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